European Leukemia Trial Registry
Trial: B1931022

More Details
Title Inotuzumab Ozogamicin Versus Investigator's Choice Of Chemotherapy In Relapsed Or Refractory ALL
Scientific Title An Open-Label, Randomized Phase 3 Study Of Inotuzumab Ozogamicin Compared To A Defined Investigator's Choice In Adult Patients With Relapsed Or Refractory CD22-Positive Acute Lymphoblastic Leukemia (ALL)
Short Title B1931022
Trialgroup NN
Type of Trial multicentric, randomized, prospective, open-label
Disease Acute lymphoblastic leukemia(ALL) Ph/BCR ABL +
Acute lymphoblastic leukemia(ALL) B-Precursor ALL
Age >= 18 years
Status Closed
Start of Recruitment 01.08.2012
Leader Stelljes, Prof. Dr. med., Matthias
Shortprotocol Shortprotocol
Remark For further information regarding the participating sites of the B1931022 trial in Europe please visit
created 21.05.2013 Johannes Kraus
changed 03.05.2018 Student Studienregister
ELIC European Leukemia Information Center | no responsibility is taken for correctness and completeness of this information | |